|1.||Monie, Archana: 1 article (07/2011)|
|2.||Zeng, Qi: 1 article (07/2011)|
|3.||Wu, T-C: 1 article (07/2011)|
|4.||Yang, Ming: 1 article (07/2011)|
|5.||Peng, Shiwen: 1 article (07/2011)|
|6.||Pang, Xiaowu: 1 article (07/2011)|
|7.||Hung, Chien-Fu: 1 article (07/2011)|
|8.||Lee, Seung-Hoon: 1 article (10/2006)|
|9.||Lee, Tae-Young: 1 article (10/2006)|
|10.||Lee, Jong-Soo: 1 article (10/2006)|
09/01/1999 - "The aim of this study was to generate HPV-16 E7 peptide-specific cytotoxic T lymphocytes (CTLs) in vitro for future adoptive immunotherapy of cervical cancer. "
10/01/2006 - "The mounting of a specific immune response against the human papillomavirus type 16 E7 protein (HPV16 E7) is important for eradication of HPV16 E7-expressing cancer cells from the cervical mucosa. "
07/01/2011 - "Furthermore, we observed that the combination of DMXAA with HPV-16 E7 peptide vaccination generated a significant enhancement in the antitumor effects in the cervicovaginal TC-1 tumor growth model, which closely resembles the tumor microenvironment of cervical cancer. "
07/15/1997 - "We identified HLA-A*0201-restricted HPV-16 E7 peptide-specific CTLs in the peripheral blood (four of five patients), draining lymph nodes (three of four patients) and tumors (one of three patients) of cervical cancer patients. "